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Background
A blinded, placebo-controlled, multi-center study was
completed in South Africa to determine virological
response of treatment-naïve CDC-2 HIV-1 infected sub-
jects receiving VGV-1 injections. The primary endpoint
was the proportion of subjects with >0.5 log decrease in
HIV-RNA.
Methods
138 subjects with mean CD4 of 336 cells/ul and mean
HIV-RNA of 4.9 log were enrolled in this GCP, ICH-com-
pliant study. Subjects were randomized to receive either
VGV-1 monotherapy (bovine-derived thymus nuclear
protein in alum, presumable immune modulator) or con-
trol via 16 biweekly i.m. injections and followed to 240
days. Effects of antiretrovirals, provided to disease pro-
gressors, were excluded from analysis.
Results
Statistically significant antiviral responses were observed
in treated subjects versus placebo (22.2% vs. 6.25%, p =
0.024) 100 days after dosing (day 150). Effects waned
(15.6% vs. 6.25%, p = 0.128) 190 days after dosing (day
240). Antiviral responses were more common in
immune-compromised (baseline CD4<300 cells/ul) sub-
jects at day 150 (35.7%, p = 0.019) and day 240 (25%, p
= 0.0479) compared to placebo. There were no serious
adverse events observed in relation with the VGV-1 injec-
tions.
Conclusion
Bioactivity of VGV-1 was confirmed and it was well toler-
ated without apparent safety concerns vs. control. Further
study to optimize dosing and clarify mechanism is war-
ranted.
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